Market Place
Sourcing Support
4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq
28 Jun 2022 //
BUSINESSWIRE
4D pharma Presents Trial on Study of MRx0518 in Combination with BAVENCIO
26 May 2022 //
BUSINESSWIRE
4D pharma to Present at the H.C. Wainwright Global Investment Conference
19 May 2022 //
BUSINESSWIRE
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004
17 May 2022 //
BUSINESSWIRE
4D pharma Reports Full Year 2021 Financial Results
31 Mar 2022 //
BUSINESSWIRE
Despite 0% response rate, 4D hits primary goal in cancer trial
24 Mar 2022 //
FIERCEBIOTECH
Parkinson’s disease: Can an early phase live biotherapeutic make waves?
03 Mar 2022 //
CLINICALTRIALSARENA
4D pharma to Participate at the Chardan Medicines Summit
23 Feb 2022 //
BUSINESSWIRE
FDA Clears 4D pharma`s IND for Live Biotherapeutics MRx0005 and MRx0029
22 Feb 2022 //
BUSINESSWIRE
4D pharma receives US regulatory green light for phase I trial in Parkinson`s
22 Feb 2022 //
PRESS RELEASE
4D pharma Shows Addnl. +ve Data From Part A of Phase I/II Trial Of MRx-4DP0004
27 Jan 2022 //
BUSINESSWIRE
4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape
20 Jan 2022 //
BUSINESSWIRE
4D Pharma Shows +ve Topline Results From Part a of PI/II Trial of MRx-4DP0004
13 Dec 2021 //
BUSINESSWIRE
4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix
09 Dec 2021 //
BUSINESSWIRE
4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518
15 Sep 2021 //
BUSINESSWIRE
4D pharma to Participate in Upcoming Virtual Investor Conferences in September
09 Sep 2021 //
BUSINESSWIRE
4D pharma Announces Two Presentations at ESMO Congress 2021
02 Aug 2021 //
BUSINESS WIRE
4D pharma Announces $30 Million Credit Facility with Oxford Finance
29 Jul 2021 //
BUSINESSWIRE
4D pharma Announces Passing of Chief Financial Officer John Beck
26 Jul 2021 //
BUSINESSWIRE
4D pharma Publishes Preclinical Research on Megasphaera massiliensis
06 Jul 2021 //
BUSINESSWIRE
4D pharma to Participate in Ladenburg Thalmann Healthcare Conference
29 Jun 2021 //
BUSINESSWIRE
4D pharma to Present at the Microbiome Movement Drug Development Summit
22 Jun 2021 //
BUSINESSWIRE
4D pharma Presents Additional Positive Results of Phase II Study of Blautix®
24 May 2021 //
BUSINESSWIRE
4D pharma to Present Additional Data from Phase II Study of Blautix
17 May 2021 //
BUSINESSWIRE
4D pharma Collaborates With Parkinson’s UK to Establish Patient Advisory Board
19 Apr 2021 //
BUSINESSWIRE
4D pharma Announces Completion of Merger With Longevity Acquisition Corporation
22 Mar 2021 //
BIOSPACE
4D Pharma Announces U.S. SEC Declares Registration Statement Effective Respect
26 Feb 2021 //
BUSINESSWIRE
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
03 Feb 2021 //
PRNASIA
4D Pharma Presents Update on Oncology Program
03 Feb 2021 //
BUSINESSWIRE
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
03 Feb 2021 //
PRNEWSWIRE
4D pharma plc Files SEC Forms in Process to Gain NASDAQ Listing Following Merger
27 Nov 2020 //
BUSINESSWIRE
4D pharma a pharma company leading the development of Live Biotherapeutic
09 Nov 2020 //
PRESS RELEASE
4D Pharma Presents New Data from Two MRx0518 Clinical Trials
09 Nov 2020 //
BUSINESSWIRE
4D Pharma to Host Virtual KOL Event Reviewing New Data Presented
05 Nov 2020 //
BUSINESSWIRE
Longevity Acquisition Corporation Announces Signing of Merger Agreement
21 Oct 2020 //
BIOSPACE
4D pharma announces three presentations at (SITC) Annual Meeting 2020
14 Oct 2020 //
PHARMIWEB
4D pharma treats first cancer patients in Part B of Phase I/II trial of MRx0518
06 Jul 2020 //
PRESS RELEASE
Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 open
02 Jul 2020 //
4DPHARMAPLC
4D Announce New Study of MRx0518 in Pancreatic Cancer
06 Jan 2020 //
PR NEWSWIRE
4D Pharma Collaborates With MSD to Develop Live Biotherapeutics for Vaccines
08 Oct 2019 //
PRNEWS WIRE
